Back |

MATTAWAN, MI April 18, 2009:
At the 100th annual meeting of the American Association for Cancer Research (AACR) being held April 18-22 in Denver, Zheng "Jim"Wang, PhD, Director of Molecular Imaging and Senior Study Director at MPI Research, will present a poster on the use of a new imaging agent for earlier tumor detection:

Micro/PET/CT Evaluation of 64^Cu Labeled Bevacizumab as a New Tumor Early Detection Probe for PET Imaging in Breast Cancer Orthotopic and Bone Metastasis Model Compared with ¹⁸FDG (abstract # LB-281)

Session title: Late-Breaking Research: Tumor Biology 2
Session schedule: 8 a.m. – noon
Session location: Poster board 10 in Hall B-F, Poster section 14

Dr.Wang and his group are the first to show that a compound made up of the anti-cancer drug, bevacizumab, and 64^Cu (a radioactive copper nuclide) is superior to the gold standard ¹⁸FDG in detecting early tumors in animal models. Because it uses different biological mechanisms compared with ¹⁸FDG, bevacizumab can detect a broader range of tumor types, can be useful in measuring tumor size, can be of value in monitoring the therapeutic impact of treatment, and may even help the radiation oncologist determine clinical treatment volume.

MPI Research provides comprehensive drug development services for the pharmaceutical, biotech, medical device, animal health, and chemical industries. To further discuss capabilities throughout the company as well as within the Discovery Center at MPI Research, please feel free to contact Dr.Wang at +1.269.668.3336, ext. 2286 or Zheng.Wang@mpiresearch.com. Visit us online at www.mpiresearch.com.


Home | News